AU2021404974B2 - Solid forms of a cdk2 inhibitor - Google Patents

Solid forms of a cdk2 inhibitor Download PDF

Info

Publication number
AU2021404974B2
AU2021404974B2 AU2021404974A AU2021404974A AU2021404974B2 AU 2021404974 B2 AU2021404974 B2 AU 2021404974B2 AU 2021404974 A AU2021404974 A AU 2021404974A AU 2021404974 A AU2021404974 A AU 2021404974A AU 2021404974 B2 AU2021404974 B2 AU 2021404974B2
Authority
AU
Australia
Prior art keywords
cancer
ppm
crystalline
values
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021404974A
Other languages
English (en)
Other versions
AU2021404974A1 (en
AU2021404974A9 (en
Inventor
Fengjuan CAO
Kevin Francis DEBOYACE
Michael HEBERLEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2021404974A1 publication Critical patent/AU2021404974A1/en
Application granted granted Critical
Publication of AU2021404974B2 publication Critical patent/AU2021404974B2/en
Publication of AU2021404974A9 publication Critical patent/AU2021404974A9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cereal-Derived Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021404974A 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor Active AU2021404974B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130530P 2020-12-24 2020-12-24
US63/130,530 2020-12-24
PCT/IB2021/062082 WO2022137106A1 (en) 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor

Publications (3)

Publication Number Publication Date
AU2021404974A1 AU2021404974A1 (en) 2023-07-06
AU2021404974B2 true AU2021404974B2 (en) 2024-11-28
AU2021404974A9 AU2021404974A9 (en) 2025-04-10

Family

ID=79283019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021404974A Active AU2021404974B2 (en) 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor

Country Status (10)

Country Link
US (1) US20240076287A1 (enExample)
EP (1) EP4267563A1 (enExample)
JP (2) JP2024503235A (enExample)
KR (1) KR20230122100A (enExample)
CN (1) CN116723837B (enExample)
AU (1) AU2021404974B2 (enExample)
CA (1) CA3206153A1 (enExample)
MX (1) MX2023007699A (enExample)
TW (1) TWI823213B (enExample)
WO (1) WO2022137106A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CN118679150A (zh) * 2022-01-27 2024-09-20 益方生物科技(上海)股份有限公司 Cdk2抑制剂及其制备方法和用途
WO2024046443A1 (en) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Macrocyclic compounds as selective cdk inhibitors
WO2025191482A1 (en) 2024-03-15 2025-09-18 Pfizer Inc. Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CA3128155C (en) * 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2

Also Published As

Publication number Publication date
MX2023007699A (es) 2023-07-10
KR20230122100A (ko) 2023-08-22
TW202233606A (zh) 2022-09-01
AU2021404974A1 (en) 2023-07-06
JP2026123057A (ja) 2026-07-29
WO2022137106A1 (en) 2022-06-30
TWI823213B (zh) 2023-11-21
JP2024503235A (ja) 2024-01-25
EP4267563A1 (en) 2023-11-01
CN116723837B (zh) 2026-05-26
CN116723837A (zh) 2023-09-08
CA3206153A1 (en) 2022-06-30
AU2021404974A9 (en) 2025-04-10
US20240076287A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
US12570641B2 (en) Solid forms of a CDK4 inhibitor
US20240076287A1 (en) Solid forms of a cdk2 inhibitor
US12030873B2 (en) 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
US20230321042A1 (en) Combination therapy
US20240000783A1 (en) Combination therapy
CN117337293A (zh) 固体形式的eif4e抑制剂
JP2025540560A (ja) Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
RU2850825C1 (ru) Твердые формы ингибитора cdk2
CA3195063C (en) Solid forms of the cdk4 inhibitor pf-07220060
RU2856216C1 (ru) Твердые формы ингибитора cdk4
HK40096368A (en) Solid forms of a cdk2 inhibitor
BR112023004713B1 (pt) Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica
HK40087859A (en) Solid forms of a cdk4 inhibitor
HK40125945A (en) Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
SREP Specification republished